Icagen, Inc. · Durham, NC United States
| 4222 Emperor Blvd., Ste. 350 | Phone: 919-941-5206 |
| Durham, NC | Fax: 919-941-0813 |
| 27703 | |
| United States | 
Map This Company |
Icagen, Inc. Rankings
Company Description
Icagen wants to set the market for ion channel modulators on fire. The development-stage biotech focuses on treatments for epilepsy, asthma, pain, and inflammation by regulating the inflow into cells of such ions as calcium, potassium, and sodium. Icagen's lead candidate, senicapoc for sickle cell disease, died in 2007 following lackluster Phase III clinical trial results. The drug was being developed in a partnership with
Icagen, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | PrivateSingle Location |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 38 |
Executives
20 executives listed for Icagen, Inc.'s Durham, NC location.
| Chairman | Charles Sanders | |
|---|---|---|
| President, CEO, and Director | P. Kay Wagoner | |
| EVP Finance and Corporate Development, CFO, and Treasurer | Richard Katz |